Abstract
Background and Objective: Loss of ovarian function after menopause affects bone metabolism and structure. The present study examined the synergistic effects of Estradiol (E2) and Resveratrol (RES) on Bone Mineral Contents (BMC) and Bone Mineral Density (BMD) and biomarkers of bone remodelling in ovariectomized rats. Materials and Methods: For this purpose, this study was conducted on five (n = 10) groups of female Sprague Dawley rats which were classified into: (1) Sham group, (2) Ovariectomized rats (OVX), (3) Ovariectomized then treated with resveratrol (OVX+RES), (4) Ovariectomized treated with estradiol (E2) ( OVX+E2) and (5) Ovariectomized treated with (OVX+RES+E2). After 16 weeks, we measured Bone Mineral Density (BMD), Bone Mineral Content (BMC) were assayed in the tibia. Also, we assayed the serum levels of the bone turnover markers as deoxypyridinoline (Dpd), N-telopeptide of type I collagen (NTxI), Alkaline Phosphatase (ALP) and osteocalcin (OC) as well as Receptor Activator of Nuclear Factor Kappa B (RANk) and Osteoprotegerin (OPG). Results: OVX reduced both BMD, BMC, OPG, ALP, OC and increased RANK, DPD and NTXI significantly (p<0.05) as compared to sham rats. RES or E2 corrected the hypogonadism induced osteoporosis by inhibiting osteoclastogenesis as compared to OVX rats. RES and E2 produced comparable effects as compared to RES and E2 treated rats. Conclusion: As RES and E2 increased BMD and BMC after ovariectomy a combination of RES and E2 might be used as a potential therapeutic for osteoporosis in the female after menopause.